Rasmus Bech Hansen
@rasbech
Followers
476
Following
476
Media
36
Statuses
953
@airfinity founder. Better knowledge dissemination will save lives.
London
Joined March 2009
The global divergence widens - thanks for important use of @Airfinity data @GitaGopinath
Three charts highlight the dangerous divergence in prospects across advanced economies and many emerging markets and developing countries. [1/] Divergences in vaccine access.
0
0
2
Congratulations to the @nytimes on the Public Service #Pulitzer Award! The need for real-time, reliable data has never been more pressing and the pandemic has shown how critical independent quality #journalism is to better decision making and public trust.
The staff of The New York Times has won the Pulitzer Prize for Public Service for coverage of the pandemic. Here are the award-winning pieces. https://t.co/ghMdQs0W4J
0
1
0
How much vaccine will be produced this year? The third article of the series created in partnership with @SimonEvenett highlights the critical importance of globally distributing the huge number of vaccines likely to be produced this year. #CovidVaccine
https://t.co/jF21WA7vJh
0
6
2
This was a great discussion, highly recommend listening in - I learned a lot. Thanks for the invite @TimHarford
Listen to "How to Vaccinate the World" now on @BBCr4today: @Airfinity CEO @rasbech, @natashaloder of the @TheEconomist and @DrPaulOffit are asked by @TimHarford what we have learned in the past four months. https://t.co/sStuu6Psk9
#COVID19 #vaccination
2
1
11
.@TheLancetInfDis reports on the hope for #Europe to reach #immunisation by the end of Summer including @Airfinity insights predicting some countries reaching that level of protection only later this year. https://t.co/Z7Jjdv1zij
thelancet.com
When the COVID-19 pandemic hit Europe in early 2020, people were forced, for the first time, to comply with what were perceived as Orwellian, almost nightmarish, restrictions. Yet, Europeans adapted...
0
5
4
Our #COVID19 vaccine insight of the day is our view on total doses produced and the number of doses that have actually been exported across countries/regions.
15
175
305
Thank you for the interview @rhysblakely @thetimes. Great to discuss our forecast on the effect of UK’s #covid19vaccine approach. https://t.co/JZKQO48pmW
1
1
3
The enormous return on investment reflects the immense scale of the damage caused by the pandemic, @rasbech told @thetimes. “Vaccine production costs billions. But you get benefits in the order of trillions, so it’s worth doing.” 7/7 Read the full story: https://t.co/csqvKylVS4
thetimes.com
Britain is on course to immunise all adults against the coronavirus about two months before the European Union, an achievement forecast to be worth tens of billions of pounds, according to an...
0
1
2
The vaccine market is being transformed by COVID-19. Airfinity data predicts vaccine sales of @Novavax and @moderna_tx overtakes 3 of the largest existing players.
ft.com
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
0
4
4
The biggest surprise of the vaccine delays to me was that it caught so many by surprise. But @TimHarford explains well why even that shouldn't be a surprise.
Why does so much from vaccines to our home work get delayed? @TimHarford makes some astute observations on the "planning fallacy" here citing @rasbech . Valuable insights for anyone planning ahead during a pandemic.
1
2
9
Glad to take part here. Scaleable, globally deployable mRNA production could be an important part of the solution to the current supply constraints.
We cannot vaccinate the world until the end of 2022, raising the risk of further dangerous variants and endemic Covid-19, warns @rasbech of @airfinity Endemic Covid raises the challenge of annually vaccinating the whole world. Full interview at: https://t.co/Mo3uz8QfOe
0
4
6
The unexpected parts of J&J and Novovax’ vaccine results are the high impact of the new variants. Big implications for the world.
0
0
2
Glad that @Airfinity is collaborating with the brilliant C-19 team at the @FinancialTimes. I think the many journalists working day and night to accurately inform the public in a sea of misinformation are among the unsung heroes of this pandemic and we are proud to support them.
How should countries and international bodies build an effective vaccine responses? Our data suggests a broad range of accelerated public investments in trials, manufacturing, supply chain security and multi-technology investments are critical. Important piece in @FT .
0
0
3
Thank you for sharing @Airfinity data @EricTopol . With flurry of vaccine deals this changes daily. Here are numbers as of today (13th Dec). Happy to share more details.
public.flourish.studio
A Flourish story by Matt Linley
Before the vaccine problems with Sanofi-GSK (wrong dose) and Astra Zeneca/Oxford (? dose) the US was already short in covering its population https://t.co/dT59rKbF4N /2
0
1
1
So true, and not just life science. Need it for energy, battery, plastic replacements and carbon capture as well.
All drug development should be like Operation Warp Speed. Alzheimer’s, Cancer. Mental health. And many more. Need this sense of urgency in government and industry all the time. Every day.
0
0
0
Japan secured has less vaccines per capita than other countries and is relying on import of vaccines. However, Novovax is partly produced in Japan and a deal with them could speed up return to normal (if the vaccine is effective). Feel free to write sars-cov-2@airfinity.com
@rasbech @Airfinity Can you please explain why you have said Japan won't see a return to normal until 2022? What are you basing this on?
2
1
3
Here is our most recent trial forecast. The delay of Novovax and possibly delay of AZ approval until post US trial readout has significant time line implications.
@rasbech Do you have any updated forecasts in public? Thank you.
1
0
0
Belated thank you David for having me on and also glad to see you found good use of the production and immunisation forecasts.
Many thanks for fascinating #vaccine insights from @DrSophieHarman and @rasbech @Airfinity - after momentous breakthroughs there’s now a hard slog on production and distribution
1
0
3